NEWSROOM Press Releases

    254 Results

    Biodesix® Named Innovative Company of the Year at 2016 IQ Awards

    Biodesix won the BizIQ award, 2016 Innovative Company of the Year.

    Biodesix’ GeneStrat Blood-Based Mutation Test Now Includes EML4-ALK Fusions

    GeneStrat blood-based mutation testing for advanced lung cancer offers significant advantages for patients and their treating physicians over standard tissue testing, which can delay treatment.

    Biodesix’ VeriStrat Test Now Covered By Humana, Medical Mutual of Ohio, PreferredOne

    Humana, Medical Mutual of Ohio and Preferred One independently determined and published a policy stating that VeriStrat can be considered medically necessary for patients with (NSCLC)

    Biodesix Presentation at Molecular Med Tri-Conference: “Blood-Based Cancer Immunotherapy Diagnostics”

    Dr. Heinrich Roder, will present the company’s approach and recent results for a blood test stratifying patients for immunotherapy benefit on Thursday, March 10, at Molecular Med Tri-Conference.

    More Information on Disease State and Trial Options for Patients with Advanced Non-Small Cell Lung Cancer; Evaluating Automated and Manual Workflows in cfDNA Extraction

    Biodesix, in partnership with BioRad and Qiagen, presents data from new studies at AMP.

    Norgen Biotek Corp. Announces Supply Agreement with Biodesix Enabling the First EML4-ALK Liquid Biopsy Test with Results in 72-Hours

    Biodesix has selected Norgen Biotek to supply sample preparation products for its EML4-ALK blood test.

    VeriStrat® Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy

    VeriStrat® Test identifies patients with squamous cell carcinoma of the lung who are more likely to have improved survival on Afatinib therapy.

    Independent Study Data Supporting Clinical Use of Biodesix®’ Blood-Based Tests To Be Presented At CHEST Conference

    Independent Study Data supports clinical use of Biodesix’s blood-based tests at CHEST conference.

    Biodesix®’ VeriStrat® Test Identifies T790M-Mutated Advanced Non-Small Cell Lung Cancer Patients Who Are More Likely to Have Improved Progression-Free Survival on Third Generation EGFR-TKI Therapy

    Biodesix's VeriStrat test identifies T790M-mutated advanced non-small cell lung cancer patients who are more likely to have improved progression-free survival on third generation EGFR-TKI therapy

    Biodesix Presenting Results From Three Studies at SITC Annual Meeting; Oral Poster Presentation, Two Additional Poster Presentations

    Biodesix will present data from three studies at SITC's annual meeting.

    Biodesix to Present Data from Three Studies Indicating the Utility of Blood-Based Diagnostic Tests at AACR Annual Meeting

    Biodesix to present data from three studies indicating the utility of blood-based diagnostic tests at the AACR annual meeting

    Biodesix Completes Series F Financing

    Biodesix raised $22 million through the sale of series F preferred stock and other securities. 

    Biodesix to Present at Leerink Partners 5th Annual Global Healthcare Conference

    Biodesix CEO David Brunel will present a corporate overview on Deep Phenotyping, Machine Learning to Precision Medicine at the Leerink Partners Conference

    Multi-Institutional Data Supporting Clinical Use of Biodesix’ Blood-Based Tests Presented Today at IASLC Conference

    Multi-institutional data supporting clinical use of Biodesix blood tests was presented at the IASCL Chicago thoracic conference

    Wellmark BCBS of Iowa and South Dakota Provides Coverage for VeriStrat® Test

    Biodesix press release: Wellmark BCBS of Iowa and South Dakota provides coverage for VeriStrat® Test

    Biodesix’s Diagnostic Cortex™ Platform Used in Three Studies Presented at SITC

    The study results indicate that the tests have the potential to offer clinically relevant information that could help physicians selecting immunotherapies for their patients make the best decision

    Biodesix® Tests Demonstrate Ability to Stratify Patients Treated with Immunotherapy

    Biodesix presents data at the World Lung Conference showing the ability to stratify lung cancer patients treated with immunotherapy

    Biodesix’ Nicholas Dupuis, Ph. D, Speaking at MSACL 3rd Annual Conference

    Biodesix’ Nicholas Dupuis, Ph. D, Speaking at MSACL 3rd Annual Conference

    Independent Data Demonstrates Clinical Utility of Biodesix®’ Blood-Based Tests

    Data from an independent study demonstrated the clinical utiity of Biodesix' VeriStrat and GeneStrat tests.

    Horizon Blue Cross Blue Shield of New Jersey Provides Coverage for Biodesix’ VeriStrat Test

    Horizon Blue Cross Blue Shield (BCBS) of New Jersey has determined that the VeriStrat® proteomic test is now considered a medically necessary benefit for members with advanced NSCLC.

    Heinrich Roder to speak at 6th International Conference on Bioinformatics & Systems Biology

    Heinrich Roder will speak at the 6th International Conference on Bioinformatics and Systems Biology

    Biodesix Raises Follow-On Series F Financing

    Biodesix raises an additional $7 million in series F financing.

    200 Million Americans Now Have Insurance Coverage for Biodesix’ VeriStrat Test

    With positive coverage decisions from BCBS Florida and HCSC, 200 million Americans now have insurance coverage for VeriStrat testing.